USANA Health Sciences Chief Information Officer Benedict Peter Acquires Additional Stock Through Restricted Stock Unit Vesting

Restricted Stock Unit Vesting Drives Insider Share Acquisition

The primary transaction disclosed in the filing involved the vesting of 598 restricted stock units (RSUs), which converted to common shares of USANA Health Sciences stock on July 25, 2026. According to the disclosure, each restricted stock unit represents a contingent right to receive one share of company common stock. This vesting represents a portion of Peter's equity compensation arrangement with the company, structured to align executive interests with shareholder value creation over an extended timeframe.

The vesting schedule outlined in the filing indicates that Peter's RSUs vest at a rate of 25% on each anniversary of July 25, 2024. This staggered vesting approach is typical of modern executive compensation packages, designed to encourage long-term retention and sustained commitment to company strategy and performance. With 38,004 RSUs remaining in Peter's beneficial ownership following this transaction, additional vesting events are expected to occur over the coming years based on the disclosed schedule.

Simultaneous Share Disposition at $21.32 Per Share

On the same trading date, Peter disposed of 176 shares at a price of $21.32 per share, according to the regulatory disclosure. This sale reduced the net share acquisition from the vesting event, resulting in a final beneficial ownership position of 422 shares from the day's transactions. The specific pricing of the disposition transaction provides data points regarding USANA Health Sciences stock valuation at the time of the insider activity.

The simultaneous acquisition through vesting and disposition through sale is a common pattern among company executives and often reflects personal financial planning, tax management strategies, or portfolio rebalancing rather than any particular statement about management's outlook for the company. Insiders frequently execute such transactions to fund personal needs or maintain diversified investment portfolios while retaining a meaningful stake in their employer.

Peter's Expanded Direct Ownership Position

The filing indicates that Benedict Peter holds 598 shares of common stock directly following the reported transactions. This direct ownership represents shares beneficially owned through unencumbered title, as distinguished from shares held through derivative securities or other indirect ownership structures. Direct share ownership by company officers is a commonly monitored metric by investors analyzing insider commitment and alignment with shareholder interests.

Beyond his direct common share holdings, Peter maintains substantial beneficial ownership through his RSU portfolio. The 38,004 restricted stock units disclosed in Table II of the filing represent significant deferred compensation that will convert to common shares over time. This multi-layered ownership structure, combining direct shares, vested RSUs, and future vesting arrangements, creates substantial equity exposure for the Chief Information Officer and demonstrates meaningful financial commitment to USANA Health Sciences' long-term performance.

Title and Role of Reporting Person

Benedict Peter serves as Chief Information Officer of USANA Health Sciences Inc., a position that typically encompasses responsibility for the company's information technology infrastructure, cybersecurity, data management systems, and technology strategy. As an officer of the company, Peter is subject to insider trading reporting obligations under Section 16 of the Securities Exchange Act of 1934. The disclosure confirms Peter's status as an officer and reporting person for purposes of SEC regulation.

The Chief Information Officer role has grown increasingly critical in contemporary corporate governance, particularly for companies in regulated industries such as nutritional products and wellness services. Peter's continued equity acquisition through the company's equity compensation program may indicate confidence in the organization's strategic direction and long-term value creation potential. Executive officers frequently monitor their compensation arrangements and equity positions as indicators of management's commitment to company success.

Timing and Transaction Details

The earliest transaction date disclosed in the filing was July 25, 2026, with the regulatory filing submitted to the Securities and Exchange Commission on July 27, 2026. This two-day filing delay falls within the standard timeframe for Form 4 submission, which requires filing within two business days following the reportable transaction. The timing of the filing reflects standard SEC compliance procedures for insiders disclosing changes in beneficial ownership.

The disclosure documents two separate transaction codes associated with the July 25, 2026 activity: an "M" code indicating equity compensation (the RSU vesting), and an "F" code indicating an open-market sale. This dual-transaction approach demonstrates the complexity of modern executive compensation arrangements, where equity awards, cash proceeds, and share dispositions may occur simultaneously as part of an integrated financial strategy.

Beneficial Ownership and Direct Holding Structure

All of Peter's shareholdings disclosed in the filing are held directly, as indicated by the "D" designation in the ownership form column of both Table I and Table II. Direct beneficial ownership means that Peter has unencumbered title to the securities and full voting and economic rights associated with the shares. This direct holding structure contrasts with indirect ownership arrangements that might involve trusts, partnerships, or other legal entities.

The filing's remarks section notes that Joshua Foukas, identified as attorney-in-fact, signed the document on behalf of Peter on July 27, 2026. The use of a power of attorney is a common administrative practice that allows authorized representatives to execute regulatory filings on behalf of corporate officers. This procedural delegation does not affect the substance of the reported transactions or the accuracy of the beneficial ownership information disclosed.

USANA Health Sciences Executive Compensation Structure

The restricted stock unit awards disclosed in this filing provide important context regarding USANA Health Sciences' executive compensation philosophy and practices. The use of RSUs with multi-year vesting schedules is designed to retain executive talent while creating alignment between management interests and shareholder value creation. The specific vesting terms outlined in the filing—25% annual vesting beginning from the grant anniversary—represent a standard approach in contemporary executive compensation design.

The presence of 38,004 unvested RSUs in Peter's beneficial ownership suggests that the company has made substantial equity grants to its Chief Information Officer. These remaining RSUs will convert to common shares at a rate of approximately 25% per year on the anniversary of July 25, 2024, creating a predictable schedule of future share acquisitions for the executive. This structure incentivizes continued service and performance while providing executives with material equity stakes in the company's long-term success.

Insider Trading Compliance and Reporting Framework

The Form 4 filing represents a required disclosure under Section 16 of the Securities Exchange Act of 1934, which mandates that officers, directors, and beneficial owners of more than 10% of a company's equity securities report changes in their beneficial ownership. Benedict Peter's disclosure as an officer of USANA Health Sciences ensures that investors have access to current information regarding executive share transactions and ownership positions. These transparency requirements serve to promote market integrity and informed investment decision-making.

The filing format and content comply with SEC regulations and rules governing insider trading disclosures. The document includes all required information elements, including transaction dates, security types, transaction codes, prices where applicable, and resulting beneficial ownership positions. Investors monitoring insider trading activity may use such filings as one data point among many in evaluating management actions and company conditions.

Investment Implications and Market Considerations

The timing and nature of Peter's share transactions—acquiring shares through equity compensation while simultaneously disposing of a smaller number of shares—may reflect routine portfolio management or tax optimization strategies rather than any particular commentary on management's assessment of company prospects. Insider transactions occur within the context of complex personal financial planning considerations and may not provide reliable signals regarding future company performance or stock price direction.

Investors evaluating USANA Health Sciences may consider insider ownership levels, equity grant structures, and transaction patterns as components of broader fundamental analysis. However, individual insider transactions should be analyzed in context alongside financial performance, industry trends, competitive positioning, and other substantive business factors. The immediate share price impact was not clear from available public information regarding this specific transaction.